|
Sarm compounds and methods of their application Claimed invention relates to methods of influencing composition of animal carcass by introduction of acylanilide compounds of selective androgenic receptor modulators (SARM), represented by formula , where Z stands for NO2, CN, Cl, F, Br or I; Y stands for CF3, F, Br, Cl or I; R2 stands for H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3 or NHCOCF3; R3 stands for H; Q stands for H, halogen, CF3 or CN; n=1; and m=1; or its isomer, pharmaceutically acceptable salt, crystal, N-oxide, hydrate or any their combination, where composition of carcass is subjected to impact by increase of fat-free mass, reduction of fat mass and/or reduction of percentage of fat mass; and where animals are represented by feedlot animals, beef cattle or fattening cattle. Impact on carcass composition in animals includes increase of growth indices, increase of average day gain (ADG) and increase of ratio forage:gain (F:G). Method includes feeding animals with such everyday forage, which contains formula IIIA compound. |
|
Method of treating infertility accompanying chronic endometritis with endometrial hypoplasia Invention refers to medicine, particularly gynaecology, and concerns treating infertility accompanying chronic endometritis with endometrical hypoplasia. A method involves an integrated therapy, which involves intrauterine administration of medicinal solutions and an endometrial exposure to low-frequency ultrasound (LFUS). The LFUS procedures are performed within three courses: the first course uses 0.05% chlorhexidine in the uterine cavity. The second and third courses provide using Imunofan in sterile normal saline in ratio 1/125. The therapeutic course involves performing procedures once a day, daily, from 5 to 10 procedures. The therapeutic courses are alternated with a treatment-free period of 2-3 menstrual cycles. The procedures in the therapeutic course start on the 5-9th day of menstrual cycle. The procedure involves providing the continuous intrauterine circulation of the medicinal solution with maintaining the pressure less than atmospheric pressure. The procedure is performed at ultrasonic vibration frequency 25 kHz, LFUS wave guide vibration amplitude 60-120 mcm, medicinal solution flow 100-150 ml/min, exposure 3-5 min, amount of infusion 200-300 ml. |
|
Invention relates to the pharmaceutical industry and represents a pharmaceutical composition for the treatment of a respiratory, inflammatory or obstructive disease of the respiratory tract, containing R(+) budesonide and one or more beta2-agonists, selected from albuterol, levoalbuterol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol, bitolterol, mesylate, ritodrine, arformoterol, carmoterol, bambuterol, clenbuterol, indacaterol, milveterol, vilanterol or olodanterol, and optionally one or more pharmaceutically acceptable excipients. |
|
Per orally decomposing tablet compositions, containing combinations of non-opiate analgesics Claimed group of inventions, which includes a pharmaceutical composition, a method of its obtaining, a drug form for per oral introduction with the claimed composition and a method of obtaining the drug form. The claimed invention is aimed at the pharmaceutical composition of a non-opiate analgesic/opiate analgesic, in which the non-opiate analgesic is contained in the core, opiate - in the first core coating, there is the second core coating with a water-insoluble polymer, as well as the second set of particles, containing the non-opiate analgesic and its coating with the water-insoluble polymer. |
|
Method for multimodal opioid-free postoperative anaesthesia in patients with neck and head cancers 1% nefopam is used for 48-72 postoperative hours. Nefopam is used as a component of a ternary mixture consisting of 2% lidocaine 150 ml combined with 1% tenoxicam 4 ml in 0.9% normal saline 134 ml administered intravenously by means of an infusion pump at 6-8 ml/h. |
|
Combination treatment of chronic obstructive pulmonary disease Group of inventions refers to an aerosol pharmaceutical composition for preventing or treating a patient suffering chronic obstructive pulmonary disease (COPD), which is stored in a container, to using the above composition for treating COPD, to a method for filling the above container, to a kit for preventing or treating COPD. The declared composition contains glycopyrronium chloride, formoterol dissolved in the propellant hydroxyfluoralkane, and 1M HCl. |
|
|
After a surgical site has been treated from three points at a breast base: superior internal and superior external, superior and inferior external, inferior external and inferior internal quadrants junctions, the skin is infiltrated with 0.25% Novocaine solution. Further, a long needle is used to inject 0.25% Novocaine 40 ml from the marked points into the retromammary space on either side. Besides, from the fourth point: axillary subcutaneous fat is infiltrated along a border of a greater pectoral muscle with smoothly changing the needle direction. That is followed by the infiltration anaesthesia of the skin and underlying tissues along the outline of the quadrant to be removed. What is also required is a Novocaine block of separated thoracodorsal nerve and long thoracic nerve. |
|
|
Method of treating acute postpartum endometritis Treating acute postpartum endometritis involves 2-staged regional antibacterial therapy. The first stage involves the subcutaneous administration of a combination of drug preparations: Lydase 16 units+2% lidocaine hydrochloride 1 ml, within the inguinal regional lymph glands. Keeping the needle inside, ceftriaxone 0.5 g in 2% lidocaine hydrochloride 1 ml is administered into the same region. At the second stage, regional lymphotropic therapy is conducted by feeding low-frequency ultrasound. To this effect, gauze tampons 10×10 cm soaked in a medicinal mixture containing Lydase 16 units+2% lidocaine hydrochloride 1 ml and ceftriaxone 0.5 g are placed onto the skin within a projection of the superficial inguinal ring. Sonic phoresis of this region is performed within 25 seconds at a frequency of 0.88 MHz. The therapeutic course makes 5 daily procedures. |
|
|
Method of treating radiation and interstitial cystitis Method involves instilling the Colegel ADL gel preparation every second day from the 1st to 20th day, and then Colegel DNK L two times a week from the 21st to 56th day. |
|
|
Method for combined prolonged anaesthesia assisting hip replacement Dexamethasone 8 mg and ketoprofen 100 mg is administered intravenously once prior to the operation. A lumbar plexus is blocked in a combination with a parasacral block and inserting perineural catheters to administer weak 0.2% Ropivacaine, local anaesthetic 20 ml. Paracetamol 1,000 mg is administered intravenously 30 minute before the operation is completed. After the operation is completed, the perineural catheter of the lumbar plexus is used to infuse 0.2% Ropivacaine 300 ml at 6-8 ml/hour for 4-5 days. Ketoprofen 100 mg is administered intramuscularly twice a day for 3 days. Through the perineural catheter of the parasacral plexus, 0.2% Ropivacaine 10 ml is administered twice every 12 hours. |
|
|
Present invention aims at pharmaceutical compositions containing a number of microparticles with taste masking, containing high-/low-dose therapeutic agents, at dosage forms containing the above pharmaceutical compositions (such as orally dispersible tablets), and at methods for producing these pharmaceutical compositions and dosage forms. |
|
Substituted 3-phenylpropionic acids and using them Invention refers to 3-phenylpropionic acid derivatives of formula |
|
Method for retrobulbar anaesthesia in oncological eye diseases with use of b-ray applicator Catheter is inserted into the retrobulbar space and used to introduce 2% lidocaine 1 ml and 0.5% marcaine 1 ml 15-20 minutes before applicator anchoring. The catheter is left in the retrobulbar space for 1-7 days. 10-15 minutes before removing the applicator, 2% lidocaine 0.5-1 ml and 0.5% marcaine 0.5-1 ml are introduced through the catheter. 4-6 hours after anchoring and removing the applicator, 2% lidocaine 1 ml and 0.5% marcaine 1 ml are introduced respectively additionally. |
|
|
Method of anaesthetics and prevention of inflammatory complications after median sternotomy After performing median sternotomy pericardial and mediastinal drainages are installed and sternum is sutured. After suturing sternum for length of its entire front surface, catheter is installed through skin counterpuncture, with 1.0-2.0 cm indent from lower wound edge. proximal end of catheter is fixed to subcutaneous-adipose cellular tissue with absorbable suture material, and distal part of catheter with cannula is fixed by suturing to skin with non-absorbable suture material. Local anaesthetic is introduced through installed catheter every 6 hours, with antibiotic being introduced every 8 hours. Introduction of medications is performed for 3-5 days. |
|
Claimed invention relates to a method of manufacturing a tablet by pressing a powder mixture in a press-mould plate with the formation of a tablet form, with the powder mixture including a pharmaceutically active substance and hydrated sugars, as well as exposure of the tablet form to radiation for a period of time, sufficient for heating the hydrogen-containing material in the tablet form to a temperature higher than its dehydration temperature with the tablet formation. |
|
Medical form for trans-mucousal peroral introduction of analgesic and/or antispasmodic molecules Invention relates to medicine. Described is medical form for transmucousal per oral introduction of, at least, one active substance of antispasmodic and/or analgesic action, which contains said active substance in form of base and/or in form of salt, water-alcohol solution, with alcoholic content, at least, 35° of alcohol by weight, with said active substance being present in water-alcohol solution in condition of stable and complete dissolution. Invention also relates to method of said medical form preparation and its application for treating spastic attacks. |
|
|
Agent for treating septic wounds, pus pockets and trophic ulcers Invention represents an agent for treating septic wounds, pus pockets and trophic ulcers containing betaine hydrochloride, methyluracil, trimecaine, pepsin powder and polyethylene oxide 400 with the ingredients taken in certain proportions, wt %, and polyethylene oxide 400 is taken in an amount of 87.0-84.0 ml. |
|
|
Introduction of endoscope into duodenum is realised. After that, "tight" filling of choledoch is performed through cholecystostoma with sterile solution, for instance, 0.25% Novocain. After that major duodenal papilla is catheterised and endoscopic papillosphincterotomy is carried out. |
|
|
Method of treating patients with scapulohumeral periarthrosis 10-day conventional drug therapy comprising a daily vascular therapy by intravenous drop-by-drop administration of Trental 5 ml dissolved in 0.9% normal saline 200 ml is followed by a local therapeutic exposure on the involved shoulder joint. That is ensured by intramuscular administration of a therapeutic mixture containing Depot-Medrol 1 ml - 40 mg, 2% lidocaine hydrochloride 6 ml - 120 mg and cyanocobalamine 3 ml - 1.5 ml into trigger areas of supraspinous, infraspinous, deltoid and subscapular muscles. Administering the therapeutic mixture follow the schedule: on the first therapeutic day, the therapeutic mixture is injected into the trigger areas of supraspinous and infraspinous muscles in an amount of 5 ml into each muscle once a day; on the second therapeutic day, the therapeutic mixture is injected into the trigger areas of deltoid and subscapular muscles in an amount of 5 ml into each muscle once a day; from the third to ninth therapeutic day, the therapeutic mixture is introduced in a dose of 10 ml every second day into the trigger areas of the subscapular muscle. |
|
|
Pharmaceutical composition contains drug substances and a consistency-forming base. According to the invention, it contains anaesthetics as drug substances specified in a group: anaesthesine, lidocaine, promedol and antiseptic specified in a group of: ethacridine lactate, Furacilin, dioxidine, chlorhexidine, boric acid, 0.5% silver solution in the following ratio, g in 1 ml of the mixture: anaesthetics 0.00001-0.5; antiseptics 0.00001-0.5; consistency-forming base - the rest. Besides, it contains lysozyme in an amount of 0.1-0.3 g per 1 ml of the mixture, alpha-lipoic acid as an antioxidant in an amount of 0.00001-0.5 g per 1 ml of the mixture, regenerants specified in a group of: pantothenic acid, calcium pantotenate, beta-carotene, coenzyme Q, sodium deoxyribonucleate, inosine, vitamins A, D, E, K in an amount of 0.00001-0.5 g per 1 ml of the mixture, anabolics specified in a group of: methyluracil, riboxinum, potassium orotate, orotic acid, L-carnitine in an amount of 0.00001-0.5 g per 1 ml of the mixture, glycyrrhizic acid and/or its salts in an amount of 0.00001-0.5 g per 1 ml of the mixture, recombinant interferon specified in a group of: recombinant interferon-alpha, recombinant interferon-beta, recombinant interferon-gamma in an amount of 100-1,000,000 International units, glucocorticoids specified in a group of: hydrocortisone, prenisolone, polcortolone in an amount of 0.00001-0.5 g per 1 ml of the mixture. The consistency-forming base contains the components specified in a group: hypromellose, sodium alginate, acetyl phthalyl cellulose, macrogol, polyvinylpyrrolidone. |
|
|
Method of treating mastoid diseases complicated with thrombophlebitis Treating mastoid diseases complicated with thrombophlebitis involves removing a pathologically changed bone, opening all mastoid process cells, exposing a sigmoid sinus and puncturing it with removing a thrombus. That is followed by plugging a sinus lumen with High-structure sodium alginate hydrogel matrix with pre-added dioxidine 0.03 g. The matrix surface is coated with Hydrogel Coletex AKL tissue. The antretomastoid cavity walls are covered with the same material, whereas a latex tampon pre-coated with Hydrogel Coletex-ADL tissue is used for plugging. |
|
Mixture of 0.5% Novocaine or 0.25% Lidocaine 19.0ml and venous autoblood 1.0 ml is administered into the acupuncture points fu-tu and zu-san-li once every day or every second day in total number of blocks 8-16, in an amount of 5 ml into each point at a penetration depth of 1.5-2.0 cm. |
|
|
Percutaneously absorbable preparation Invention refers to a percutaneously absorbable layer having a base and an adhesive layer which is placed on the base and which comprises an adhesive agent and a therapeutic ingredient. The adhesive agent contains a mixture of resins containing 100 portions by weight of an acrylic copolymer (A) and 0.1 to 30 portions by weight of an acrylic copolymer (B) or 0.05 to 2 portions by weight of a low-molecular polyamine compound having at least two amino groups in one molecule and non-polymerising with a polymer or an oligomer formed. The adhesive layer additionally contains an organic acid. The acrylic copolymer (A) represents an acrylic copolymer, which contains acrylic ester of (meth)acrylic acid as a main monomer ingredient and contains 3 to 45 wt % of diacetone acrylamide as a target monomer ingredient, but free from a free carboxylic group. The acrylic copolymer (B) represents an acrylic copolymer, which contains acrylic ester of (meth)acrylic acid as a main monomer ingredient and contains a primary amino group and/or carboxyhydrazidase group on side chains, but free from a free carboxylic group. |
|
|
Method for sclerotherapy of juvenile haemangiomas Antiseptic preparation is followed by the infiltration of a haemangioma floor with 2% Ropivacaine (up to 1-5 ml/cm2). Then 10-15 minutes later involving progression of vasoconstriction and anaesthesia, the ultrasound-controlled sclerotherapy of the haemangioma follows with using a foam form of 1% sodium tetradecyl sulphate. Besides, vaccination is stated contraindicated throughout the therapy. |
|
Therapeutic agent contains hypromellose, boric acid and a consistency base; it additionally contains anesthesin or lidocaine as an analgesic in an amount of 0.00001-0.5 g. |
|
|
Drug preparation contains a combination of phenylephrine hydrochloride (or an equivalent amount of the other pharmaceutically acceptable form of phenylephrine) and paracetamol. |
|
Filtration composition and method for fat excision Invention represents a composition for surgical area infiltration in liposuction or lymphedema elimination, containing normal saline, 0.5% Naropin and phosphatidylcholine in ratio 9:1:6 respectively per 10-15 cm3 fat. |
|
|
Intramesovarian blockade of ovarian and cranial uterine nerves is carried out by laparotomy and administration in the mesovarium of 0.5-1% solution of novocaine or lidocaine. Blockade is carried out by inserting the needle of the syringe into the mesovarium in the vicinity of the ovarian bursa and uterine horn at an acute angle to the surface of the ovarian mesenterium to a depth of 3-4 cm. At that 3 ml of anaesthetic is administered to small breeds of dogs and fur-bearing animals, and from 3 to 9 ml of anaesthetic is administered to large and giant breeds of dogs as from one and from the opposite side of the body. |
|
|
Method of treating sternomediastinitis Invention refers to medicine, namely to surgery, and can be used for treating sternomediastinitis. That is ensured by introducing a therapeutic mixture prepared ex tempore containing a broad-spectrum antibiotic tropic to bone tissue in a half a compendially recommended average therapeutic daily dose, 1 ml of lidase 32 thousand units, 1 ml of a lincomycine solution in a dose of 0.3 g, 1 ml of ketorolac tromethamine in a dose of 0.03 g, 1 ml of dexamethasone solution in a dose of 0.004 g, 1 ml of a 10% lidocaine solution and 5 ml of a 40% glucose solution. The therapeutic mixture is administered into interspinous ligaments of the spinal column at Th2-Th3, Th3-Th4, Th4-Th5, at a depth of 1.5-2 cm in a dose of 3 ml into each injection point into a patient lying on his/her side with bringing the knees to the stomach and bending the head as forward as possible. The length of treatment makes 12-14 days with the first 3 injections performed daily; the residual injections - every second day, 8-9 injections in total. |
|
|
Pharmacological composition contains a therapeutic agent and a pharmaceutically acceptable base. As a therapeutic agent, it contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, as well as hypromellose, boric acid as an antiseptic, anesthesin or lidocaine as local anaesthetics in the following proportions, g per 1 ml of the mixture: recombinant interferon, IU 100-10,000,000, hypromellose 0.00001-0.5, boric acid 0.00001-0.5, anesthesin or lidocaine 0.00001-0.5, a pharmaceutically acceptable base - the rest. Besides, the pharmaceutical composition contains heparin in an amount of 0.00001-0.5 g; antibiotics specified in a group of: baneocin, levomycin, tetracycline, amoxicilline in an amount of 0.00001-0.5 g. And as a pharmaceutically acceptable base, the pharmaceutical composition contains macrogol 400, or macrogol 1500, or macrogol 4000. |
|
|
Pharmaceutical composition possessing prolonged antiarrhythmic activity Invention refers to medicine, specifically to pharmaceutical compositions possessing prolonged antiarrhythmic actions and applicable to correct the cardiac arrhythmia, including that of the ischemic origin. What is presented is a pharmaceutical composition with the prolonged antiarrhythmic acitivity containing bis[2-(diethylamino)]-N-(2,6-dimethylphenyl)acetamide L-glutaminate, L-glutamic acid, 2-aminoethane sulpho-acid and excipients. |
|
|
Hexasubstituted para-aminophenols with arylamide groups in 2,6 positions with respect to hydroxyl Invention relates to novel hexasubstituted para-aminophenols: where R=C6H5, C6H4Cl, C6H4Br, C6H4CH3, with arylamide groups in 2,6 positions with respect to hydroxyl, which demonstrate antibacterial activity. |
|
Invention refers to medicine, particularly to methods of treating cystitis of various origins. Increasing the clinical effectiveness and reducing a probability of recurrences are ensured by administering therapeutically active and gel preparations possessing a high adhesion to urothelium walls. The method involves instilling sodium alginate in the form of Colegel gel containing the therapeutically active preparations dioxidine, lidocaine, deoxyribonucleate, sodium hyaluronate in a therapeutically effective amount with the instillation procedure suggested to be performed according to the schedule specified depending on the cystitis origin. If observing chronic bacterial recurrent cystitis, the following schedule is presented: instillations of Colegel-ADL from the 1st to 10th therapeutic day daily, instillations of Colegel-DNK-L from the 11th to 20th therapeutic day every second day, 2-month instillation of Colegel-Hyal once a week. Treating radiation and interstitial cystitis requires the following therapeutic schedule: instillations of Colegel-ADL from the 1st to 20th day, while Colegel-DNK-L and Colegel-Hyal are instilled once twice a week from the 21st to 56th day alternated every second day. The presented therapeutic schedules using the given therapeutically active preparations enabling relieving pain, reducing a rate and a length of recurrent cystitis. |
|
|
Method of treating perforations and disruption of lower one-third of oesophagus Invention refers to medicine, namely to thoracic surgery, and can be used to close defects of the lower one-third of the oesophagus. A laparotomy and a sagittal diaphragmotomy are performed. The oesophageal wall defect is closed with a single-layer uninterrupted absorbable mass suture. The suture is started from the proximal end of the defect with the first knot tightened into the oesophageal lumen. A fundoplication cuff is created with covering the suture with the stomach. One of the gastric walls is fixed by interrupted sutures surrounding the closed oesophageal defect to form a cavity between the closed oesophageal defect and the gastric wall. The cavity is filled with Coletex ADL hydrogel tissue. The fundoplication cuff is fixed by interrupted sutures circularly to the diaphragm. The pleural spaces, mediastinal and subphrenic space are drained. |
|
|
Invention relates to a set, containing calcium sulphate hemihydrates, pressed particles of calcium sulphate dehydrate, additionally containing one or more therapeutically, preventively and/or diagnostically active substances, and sodium-carboxymethylcellulose (Na-CMC) and a water medium, including water. The ratio R of sodium-carboxymethylcellulose and calcium sulphate in the set constitutes from 0.1 mg of sodium-carboxymethylcellulose (calculated as Na-CMC)/g of calcium sulphate to 8 mg of sodium-carboxymethylcellulose (calculated as Na-CMC)/g of calcium sulphate. When mixed, the said components of the set form a bioresorbable ceramic composition. The invention also relates to the application of the set for the treatment of a disease or condition, associated with prostate. Also claimed is a composition ready for application in the form of a paste for introduction to a patient during the time period from 5 minutes to 1 hour before hardening, obtained by mixing the components of the set. Also claimed are: a hardened composition and a method of obtaining the hardened composition or the composition ready for application. |
|
Patient is laid on his/her side opposite a block region. A guide mark is a vertical line in a projection of Petit's triangle from the twelfth rib to a wing of ilium. A needle is pricked into the skin on the vertical line at 1.5-2.5cm above the wing of ilium. 0.25% Novocaine is administered in layers into the skin and subcutaneous fat. The needle is advanced into the lumbar region from back to front in the medial direction along the lateral edge of broadest muscle of back at 6-8cm. Novocaine 120ml is administered into the lower order of the lumboiliac fossa formed in this region. |
|
Microcolloidal solution of propofol for anaesthesia Aqueous composition for anaesthesia is proposed, which comprises propofol as an active agent, the PEG-660-12-hydroxystearate as a solubiliser, benzyl alcohol, or chloroethanol or parabens as preservative, the tocopherol and arginine or glycine at a specific content of components wt %. The GABA agonists can be additionally added to the composition, e.g. aminophenyl-butyric acid, local anesthetics such as lidocaine, alpha-2-adrenoceptor agonists such as xylazine. The method is proposed for implementing anaesthesia comprising administering to a patient of an effective amount of the claimed composition. |
|
Combined preparation for treating animals suffering from bacteriosis and yeast mycosis Declared group of inventions refers to veterinary science and is applicable for treating the animals suffering from bacteriosis and yeast mycosis. A declared preparation contains oxytetracycline hydrochloride, sulphadimine, ampicillin sodium, nistatine, a solvent and the active substance conduit dimethyl sulphoxide, the quick-relief anaesthetic lidocaine in the following proportions, wt %: ampicillin sodium 4.0-8.0, oxytetracycline hydrochloride 2.0-4.0, nistatine 1.0-2.0, sulphadimine 2.0-4.0, novocaine 0.25-0.5, lidocaine 0.25-0.5, dimethyl sulphoxide 10.0-20.0, 1,2-propylene glycol - the rest. A method of treating the animals consists in administering the declared preparation in a dose of 0.1-0.2 cm3 per 1 kg of body weight. |
|
|
Compounds and formulations for active substance delivery Invention refers to compounds or their pharmaceutically acceptable salts which can be applicable for biologically active substances delivery. |
|
At the first stage a puncture of the right femoral artery or the right radial artery by Seldinger is performed with further successive catheterisation of the mouth of superior and inferior mesenteric arteries. After that, infusion of 0.5 ml of a 15% solution of xantinol nicotinate and 1.0 ml of a 2% lidocaine solution, diluted in 20.0 ml of a 0.9% solution of sodium chloride is performed. Introduction is carried out under X-ray control. |
|
|
Method of treatment and prevention of recurrences of intrauterine synechiae For treatment and prevention of recurrences of the intrauterine synechiae within the range of pre-implantation preparation of the endometrium, heteroscopy with further installation of the child's Foley catheter into the uterine cavity is performed. The catheter balloon is filled with 2 ml of the physiological solution. The catheter is installed for 7 days, on which instillagel in a dose of 2.5 ml is introduced into the uterine cavity through holes in the distal end of the catheter on 1, 3, 5, 7 day alternating it with introduction of filgrastim in a dose of 100 mcg on 2, 4, 6 days. Instillation is realised at the background of performed hormonal therapy. |
|
Method of drug dilation of rigid pupil before performing phacoemulsification 0.05 ml of a mixture of drug solutions, consisting of three parts: 0.02 ml of a 1% adrenalin solution, 0.02 ml of a 1% mesatonum solution and 0.01 ml of a 2% lidocaine solution is introduced by injection into the area of the limb on the boundary of non-transparent and transparent parts of the cornea. Injection is performed by means of an injection needle of 27 gauge (27G) in a dose of 1/3 of the mixture volume in three points: on 12 o'clock, 4 o'clock and 8 o'clock. The needle is punctured in to the depth S of the cornea thickness. |
|
|
Method for providing higher efficacy and safety of ultrafast opioid detoxification What is involved is infusion therapy with crystalloid solutions at 15 ml/kg of a patient's body weight. That is followed by puncturing and catheterising an epidural space at the level of ThVII-ThVIII according to the standard practice and introducing a test dose of 2% lidocaine 3 ml. If observing no signs of intrathecal introduction of local anaesthetics 10 minutes later, a basic dose containing 0.75-1% naropin 10 ml or 0.25-0.5% marcaine 10 ml and clofelin 3-5 mcg/kg is introduced. Total intravenous anaesthesia follows 20 minutes after pre-medication with atropine 0.01 mg/kg, 1% diphenylhydramine 1 ml and relanium 10 mg and urethral catheterisation. A narcosis is induced with propofol in a dose of 2 mg/kg. Anaesthesia is maintained with propofol 2-4 mg/kg·h. After that, within the first hour following the detoxification, naloxone 12 mg is introduced intravenously; a naloxone measurement rate is supposed to make 0.8 mg/h for 4-5 following hours of general anaesthesia. The repeated introduction of 0.75-1% naropin 6 ml or 0.25-0.5% marcaine 6 ml and clofelin 2-3 mcg/kg into the epidural space is performed 90 minutes later. After the procedure is terminated, and the patient recovers, prolonged epidural analgesia is conducted by introducing 0.2% naropin 10 ml and clofelin 1 mcg/kg into the epidural space every 4 hours for 24-48 hours. |
|
|
Substituted aminoindans and analogues thereof to be used in pharmaceutics Invention refers to compounds of formula , wherein A means a six-merous aryl radical or a five-merous heteroaryl radical which contains one heteroatom specified in oxygen and sulphur; one or more hydrogen atoms in the above aryl or heteroaryl radicals can be substituted by substituting groups R1 which are independently specified in a group consisting of: F, Cl, Br, I, (C1-C10)-alkyl-, (C1-C10)-alkoxy-, -NR13R14; B means a radical with mono- or condensed bicyclic rings specified in a group consisting of: six-ten-merous aryl radicals, five-ten-merous heteroaryl radicals and nine-fourteen-merous cycloheteroalkylaryl radicals, wherein cycloheteroalkyl links can be saturated or partially unsaturated, while the heterocyclic groups can contain one or more heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, one or more hydrogen atoms in the radical groups B can be substituted by substituting groups R5 (as specified in the patent claim), L means a covalent bond, X means the group -O-, R2 is absent or means one or more substitutes specified in F and (C1-C4)-alkyl radical; R3 and R4 independently mean (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C4-C20)-cycloalkylalkyl, (C2-C19)-cycloheteroalkyl, (C3-C19)-cycloheteroalkylalkyl, (C6-C10)-aryl, (C7-C20)-arylalkyl, (C1-C9)-heteroaryl, (C2-C19)-heteroarylalkyl radicals, or R3 and R4 together with nitrogen attached whereto can form a four-ten-merous saturated, unsaturated or partially unsaturated heterocyclic compound which can additionally contain one or more heteroatoms among -O-, -S(O)n-, =N- and -NR8-; other radicals are such as specified in the patient claim. Also, the invention refers to using the compound of formula I for preparing a drug. |
|
Method for measuring sympathetic block in epidural anaesthesia (analgesia) Invention refers to medicine, namely to anaesthesiology and resuscitation, and may be used in epidural anaesthesia. That is ensured by administering slowly intravenously a basic dose of the local anaesthetic: 0.2-1% naropin or 0.2-0.5% marcaine, or 1-2% lidocaine; 1% Sol. Nicotini acidi 1% - 0.5-1 ml into the epidural space 10-20 minutes later. After 5-10 minutes, nicotine test results are visually evaluated by determining a clear interface of skin colour - hyperemic and normal - along an axillary line from both sides. The normal skin interface corresponds to the sympathetic block. |
|
|
Method of anaesthesia after herniorrhaphy by inguinal access in case of inguinal hernias Invention relates to medicine, namely to anaesthesiology and surgery, and can be used in case of anaesthesia necessity in patients after herniorrhaphy with inguinal access in case of inguinal hernias. For this purpose after the main stage of operation - hernioplasty, before suturing of the aponeurosis of the external oblique abdominal muscle, through subcutaneous adipose cellular tissue a puncture of 1 cm more medially and 1 cm higher than the anterior-superior iliac spine is made. A multiperforated catheter is introduced through the puncture under finger and visual control in such a way that its distal end is near the pubic tubercle. The catheter is placed under the aponeurosis of the external oblique abdominal muscle in the inguinal canal above and parallel to the spermatic cord in men or the round ligament of uterus in women. All the side holes of the catheter must be located in the subaponeurotic space. The first 48 hours of the post-operation period the local anaesthetic is continuously introduced by drop infusion at a rate of 2-4 ml/h or by bolus introduction in a dose of 10 ml each 4-6 hours through the catheter. After 48 hours the catheter is removed. |
|
Stable injectable paracetamol formulation for injections Aqueous solution contains paracetamol, a compound stabilising and dissolving paracetamol in the solution, specified in a group consisting of cyclodextrins, a stabilising compound containing a thiol functional group, and a stabilising compound specified in a group consisting of thiamine salts. Preferentially, the stabilising agents are presented by 2-hydroxypropyl-beta-cyclodextrin, monothioglycerol and thiamine hydrochloride. |
|
|
Using smoothened antagonists for treating hedgehog pathway related disorders Group of inventions is based on modulation of Hedgehog signalling transduction pathways. In more detail, the group of inventions refers to methods of treating Hedgehog related cancer. Particularly, the application describes methods of inhibition of abnormal growth conditions caused by such phenotypes, as loss of the Ptch function, dominant-negative intensification of the Hedgehog function, dominant-negative intensification of the Smoothened function or dominant-negative intensification of the Gli function consisting in administering a combination containing Smoothened inhibitors and Gli inhibitors or phosphatidylinositol-3-kinase (PI3K) inhibitors into a mammal. |
|
Method of treating superficial thermal burns Affected areas of skin are coated with dressings impregnated with therapeutic preparations containing 1.0-2.0% hypromellose, an antiseptic specified in a group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron and 2% lidocaine hydrochloride. At the stage of wound exudation on the second or third post-injury day, the dressings impregnated with 2.0% hypromellose, the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron, and 2% lidocaine hydrochloride are used and changed once a day. At the stage of proliferation, the dressings impregnated with 1.0% hypromellose and the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron are used and changed every 2 days. At the stage of epithelisation, the dressings impregnated with 1.0% hypromellose and the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron are used and changed every 3 days until the wound surface is completely epithelised. |
|
|
Method of therapy of mastitis in dogs 10 minutes prior to direct carrying out of lymphotropic and lymph-stimulating injections, furosemide is intramuscularly injected to an animal at a dose of 2 mg per 1 kg of weight. After that, the lymphotropic antibiotic therapy is carried out. Then the lymph-stimulating injection is carried - in the thickness of the interspinous ligament of the spine at the level L2-L6 the mixture is injected at a dose of 1 ml per 5 kg body weight of an animal, which consists of 32 IU Lydazum, 500 thousand IU Roncoleukinum, 4 ml of 2% lidocaine solution, and 5 ml of 40% glucose solution. The lymphotropic injections are carried out every 24 hours. The lymph-stimulating injections are carried out every 48 hours. In total 5 lymphotropic and 3 lymph-stimulating injections are carried out. |
Another patent 2551051.